Risk of hospitalization and hip fracture associated with psychotropic polypharmacy in patients with dementia: A nationwide register‐based study. (8th June 2021)

• Record Type: Journal Article
• Authors: Zakarias, Johanne Købstrup; Nørgaard, Ane; Jensen‐Dahm, Christina; Gasse, Christiane; Laursen, Thomas Munk; Palm, Henrik; Nielsen, René Ernst; Waldemar, Gunhild
• Is Part Of: International journal of geriatric psychiatry. Volume 36:Number 11(2021)
• Page Start: 1691
• Page End: 1698
• Publication Date: 2021-06-08
• Subjects: dementia -- hip fracture -- hospitalization -- psychotropic drugs; Geriatric psychiatry -- Periodicals; Geriatric Psychiatry -- Periodicals; 618.97689
• DOI: 10.1002/gps.5587
• Languages: English
• ISSNs: 0885-6230

Abstract

Abstract: Objective: To investigate the association of benzodiazepines and antidepressants on the risk of hospitalization and hip fracture in patients with dementia initiating antipsychotic drug treatment. Methods: A register‐based retrospective cohort study using data on all incident dementia cases (≥65 years) initiating antipsychotic treatment as monotherapy or in combination with benzodiazepines and/or antidepressants in Denmark from 2000 to 2015. The outcomes of interest were all‐cause hospitalization and hip fracture. Cox proportional hazards models with adjustment for multiple variables were used to investigate risk of hospitalization and hip fracture within 180 days. Results: The risk of all‐cause hospitalization during 180‐days follow‐up was significantly increased by 55% (adjusted HR: 1.55, 95% CI: 1.29–1.86, p < 0.0001), when antipsychotic use was combined with benzodiazepines, when compared to antipsychotic monotherapy. The association between the combination of antipsychotics and benzodiazepines with the risk of hip fracture did not reach statistical significance (adjusted HR: 1.50, 95% CI: 0.99–2.26, p = 0.0534). Conclusions: The observed increased risk of all‐cause hospitalization and hip fracture may indicate increased drug‐related adverse events. Thus, careful and regular monitoring is needed to assess response to treatment and decrease the risk of adverse events, when antipsychotics are combined with BZDs, albeit confounding cannot be fully excluded within the current design. Key Points: Psychotropic drugs are widely used to treat neuropsychiatric symptoms in patients with dementia. Treatment with benzodiazepines in combination with antipsychotics was associated with a 55% increased risk of hospitalization and a trend for increased risk of hip fracture. The combination of antidepressants with antipsychotics was associated with a trend for increased risk of hospitalization, but not for hip fracture. Clinicians need to be aware of the potential increased risk of hospitalization and hip fracture for patients with dementia when planning psychopharmacological treatments.